Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;32(Suppl 3):1211-1215.
doi: 10.1097/SCS.0000000000007310.

Vascular Malformations: Current Progress Toward Drug Therapy

Arin K Greene  1 , Christopher L Sudduth
Affiliations

Vascular Malformations: Current Progress Toward Drug Therapy

Arin K Greene et al. J Craniofac Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.
Major types of vascular malformations and an example of an overgrowth syndrome. (A) Capillary malformation. (B) Venous malformation. (C) Lymphatic malformation. (D) Arteriovenous malformation. (E) CLOVES syndrome.
Figure 2.
Figure 2.
Current treatment of vascular malformations with pharmacotherapy. (A) Successful management of a tongue lymphatic malformation before (above) and after (below) oral sirolimus (photos courtesy of Cameron Trenor, MD). (B) Patient with an AVM treated with oral trametinib which improved her symptoms and slowed the progression of the lesion.
Figure 3.
Figure 3.
Future of drug treatment for vascular malformations. Our goal is to develop pharmacotherapy for patients that will prevent the enlargement of their lesion. In the future, this patient will receive medicine in childhood (left) that will stop his AVM from growing to cause significant morbidity in adulthood (right).
See this image and copyright information in PMC

References

    1. Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: Recommendations from the international society for the study of vascular anomalies. Pediatrics. 2015;136(1):e203–e214. doi:10.1542/peds.2014-3673 - DOI - PubMed
    1. Greene AK, Goss JA. Vascular Anomalies: From a Clinicohistologic to a Genetic Framework. Plast Reconstr Surg. 2018;141(5):709e–717e. doi:10.1097/PRS.0000000000004294 - DOI - PMC - PubMed
    1. Shirley MD, Tang H, Gallione CJ, et al. Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ. N Engl J Med. 2013;368(21):1971–1979. doi:10.1056/nejmoa1213507 - DOI - PMC - PubMed
    1. Couto JA, Huang L, Vivero MP, et al. Endothelial cells from capillary malformations are enriched for somatic GNAQ mutations. Plast Reconstr Surg. 2016;137(1):77e–82e. doi:10.1097/PRS.0000000000001868 - DOI - PMC - PubMed
    1. Couto JA, Ayturk UM, Konczyk DJ, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis. 2017;20(3):303–306. doi:10.1007/s10456-016-9538-1 - DOI - PMC - PubMed